安徽医学
安徽醫學
안휘의학
ANHUI MEDICAL JOURNAL
2014年
5期
626-629
,共4页
孙泽华%张留福%叶志萍%王秀丽
孫澤華%張留福%葉誌萍%王秀麗
손택화%장류복%협지평%왕수려
KCNQ1%基因多态性%2型糖尿病%吡格列酮%疗效
KCNQ1%基因多態性%2型糖尿病%吡格列酮%療效
KCNQ1%기인다태성%2형당뇨병%필격렬동%료효
KCNQ1%genetic polymorphisms%Type 2 diabetes mellitus%pioglitazone%therapeutic efficacy
目的:探讨中国2型糖尿病(T2DM)患者中KCNQ1基因rs2237897多态性与T2DM的相关性及对吡格列酮疗效的影响。方法本研究采用病例-对照研究模式。使用聚合酶链反应-限制性片段长度多态(PCR-RFLP)方法对321例T2DM患者和345名健康对照者进行KCNQ1(potassium voltage-gated channel,KQT-like subfamily,member 1)基因rs2237897位点分型;选择51例患者给予连续12周每天30 mg吡格列酮治疗。检测计算体重指数(BMI)、空腹血糖(FPG)、餐后血糖(PPG)、空腹胰岛素(FINS)、餐后胰岛素(PINS)、糖化血红蛋白(HbAlc)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-c)和高密度脂蛋白胆固醇(HDL-c)等指标。结果 KCNQ1基因rs2237897多态性与T2DM相关(OR=1.918,95% CI 1.113-3.075,P<0.05)。携带KC-NQ1基因rs2237897 CT+TT基因型患者经吡格列酮治疗12周后的PPG (mmol/L)(DV -0.79±3.96 vs -2.75±3.8,P<0.05)下降值和DVPINS (mU/L)(DV 14.08±16.82 vs 28.69±19.11,P<0.05)增加值均显著低于野生CC基因型患者。结论中国汉族人群中KCNQ1基因rs2237897多态性与T2DM的易感性相关并影响吡格列酮的疗效。
目的:探討中國2型糖尿病(T2DM)患者中KCNQ1基因rs2237897多態性與T2DM的相關性及對吡格列酮療效的影響。方法本研究採用病例-對照研究模式。使用聚閤酶鏈反應-限製性片段長度多態(PCR-RFLP)方法對321例T2DM患者和345名健康對照者進行KCNQ1(potassium voltage-gated channel,KQT-like subfamily,member 1)基因rs2237897位點分型;選擇51例患者給予連續12週每天30 mg吡格列酮治療。檢測計算體重指數(BMI)、空腹血糖(FPG)、餐後血糖(PPG)、空腹胰島素(FINS)、餐後胰島素(PINS)、糖化血紅蛋白(HbAlc)、甘油三酯(TG)、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-c)和高密度脂蛋白膽固醇(HDL-c)等指標。結果 KCNQ1基因rs2237897多態性與T2DM相關(OR=1.918,95% CI 1.113-3.075,P<0.05)。攜帶KC-NQ1基因rs2237897 CT+TT基因型患者經吡格列酮治療12週後的PPG (mmol/L)(DV -0.79±3.96 vs -2.75±3.8,P<0.05)下降值和DVPINS (mU/L)(DV 14.08±16.82 vs 28.69±19.11,P<0.05)增加值均顯著低于野生CC基因型患者。結論中國漢族人群中KCNQ1基因rs2237897多態性與T2DM的易感性相關併影響吡格列酮的療效。
목적:탐토중국2형당뇨병(T2DM)환자중KCNQ1기인rs2237897다태성여T2DM적상관성급대필격렬동료효적영향。방법본연구채용병례-대조연구모식。사용취합매련반응-한제성편단장도다태(PCR-RFLP)방법대321례T2DM환자화345명건강대조자진행KCNQ1(potassium voltage-gated channel,KQT-like subfamily,member 1)기인rs2237897위점분형;선택51례환자급여련속12주매천30 mg필격렬동치료。검측계산체중지수(BMI)、공복혈당(FPG)、찬후혈당(PPG)、공복이도소(FINS)、찬후이도소(PINS)、당화혈홍단백(HbAlc)、감유삼지(TG)、총담고순(TC)、저밀도지단백담고순(LDL-c)화고밀도지단백담고순(HDL-c)등지표。결과 KCNQ1기인rs2237897다태성여T2DM상관(OR=1.918,95% CI 1.113-3.075,P<0.05)。휴대KC-NQ1기인rs2237897 CT+TT기인형환자경필격렬동치료12주후적PPG (mmol/L)(DV -0.79±3.96 vs -2.75±3.8,P<0.05)하강치화DVPINS (mU/L)(DV 14.08±16.82 vs 28.69±19.11,P<0.05)증가치균현저저우야생CC기인형환자。결론중국한족인군중KCNQ1기인rs2237897다태성여T2DM적역감성상관병영향필격렬동적료효。
Objective To investigate whether the KCNQ1 (potassium voltage-gated channel,KQT-like subfamily,member 1 )gene rs2237897 polymorphism was associated with T2DMand pioglitazone efficacy in Chinese Han T2DMpatients.Methods A total of 321 T2DM patients and 345 healthy volunteers were enrolled to identify KCNQ1 gene rs2237897 polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay.Fifty-one patients with CYP2C8*1*1 genotype were selected and given a 12-week pioglitazone treat-ment (30 mg /d).Fasting plasma glucose (FPG),postprandial plasma glucose (PPG),glycated hemoglobin (HbAlc),serum triglycerides (TG),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-c)and high-density lipoprotein-cholesterol (HDL-c)were deter-mined before and after pioglitazone treatment.Results KCNQ1 gene rs2237897 polymorphism was associated with T2DMin Chinese (OR=1.918,95% CI 1.113-3.075,P<0.05).The pioglitazone efficacy on DVPPG(differential value post prandial plasma glucose)(P<0.05) and DVPINS (differential value postprandial serum insulin)were lower in patients with rs2237897 CT+TT genotypes compared with CC geno-type carriers.Conclusions KCNQ1 gene rs2237897 polymorphism is associated with T2DM and pioglitazone therapeutic efficacy in Chinese Han population.